Tempest Therapeutics Inc (NASDAQ:TPST) shares, rose in value on Friday, March 28, with the stock price down by -8.08% to the previous day’s close as strong demand from buyers drove the stock to $0.77.
Actively observing the price movement in the last trading, the stock closed the session at $0.84, falling within a range of $0.7709 and $0.827. The value of beta (5-year monthly) was -2.57. Referring to stock’s 52-week performance, its high was $6.00, and the low was $0.70. On the whole, TPST has fluctuated by -2.36% over the past month.
With the market capitalization of Tempest Therapeutics Inc currently standing at about $33.70 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-26.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that TPST’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of TPST currently trading nearly -5.54% and -10.72% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 39.41, while the 7-day volatility ratio is showing 4.77% which for the 30-day chart, stands at 5.60%. Furthermore, Tempest Therapeutics Inc (TPST)’s beta value is -2.43, and its average true range (ATR) is 0.05.
A comparison of Tempest Therapeutics Inc (TPST) with its peers suggests the former has fared considerably weaker in the market. TPST showed an intraday change of -8.08% in last session, and over the past year, it shrunk by -79.19%%.
Data on historical trading for Tempest Therapeutics Inc (NASDAQ:TPST) indicates that the trading volumes over the past 10 days have averaged 0.38 and over the past 3 months, they’ve averaged 873.87K. According to company’s latest data on outstanding shares, there are 43.97 million shares outstanding.
Nearly 9.21% of Tempest Therapeutics Inc’s shares belong to company insiders and institutional investors own 6.51% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.75 million shares as on 2025-03-14, resulting in a short ratio of 3.01. According to the data, the short interest in Tempest Therapeutics Inc (TPST) stood at 437.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 2.11 million. The stock has fallen by -7.48% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the TPST stock heading into the next quarter.
